JP2012505247A5 - - Google Patents

Download PDF

Info

Publication number
JP2012505247A5
JP2012505247A5 JP2011531221A JP2011531221A JP2012505247A5 JP 2012505247 A5 JP2012505247 A5 JP 2012505247A5 JP 2011531221 A JP2011531221 A JP 2011531221A JP 2011531221 A JP2011531221 A JP 2011531221A JP 2012505247 A5 JP2012505247 A5 JP 2012505247A5
Authority
JP
Japan
Prior art keywords
fluoro
alkyl
group
methyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011531221A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012505247A (ja
JP5632379B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/060237 external-priority patent/WO2010042867A2/en
Publication of JP2012505247A publication Critical patent/JP2012505247A/ja
Publication of JP2012505247A5 publication Critical patent/JP2012505247A5/ja
Application granted granted Critical
Publication of JP5632379B2 publication Critical patent/JP5632379B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011531221A 2008-10-09 2009-10-09 ヒトピルビン酸キナーゼ活性化剤 Active JP5632379B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10409108P 2008-10-09 2008-10-09
US61/104,091 2008-10-09
PCT/US2009/060237 WO2010042867A2 (en) 2008-10-09 2009-10-09 Activators of human pyruvate kinase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014207672A Division JP5960770B2 (ja) 2008-10-09 2014-10-09 ヒトピルビン酸キナーゼ活性化剤

Publications (3)

Publication Number Publication Date
JP2012505247A JP2012505247A (ja) 2012-03-01
JP2012505247A5 true JP2012505247A5 (enExample) 2012-10-04
JP5632379B2 JP5632379B2 (ja) 2014-11-26

Family

ID=41462200

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011531221A Active JP5632379B2 (ja) 2008-10-09 2009-10-09 ヒトピルビン酸キナーゼ活性化剤
JP2014207672A Active JP5960770B2 (ja) 2008-10-09 2014-10-09 ヒトピルビン酸キナーゼ活性化剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014207672A Active JP5960770B2 (ja) 2008-10-09 2014-10-09 ヒトピルビン酸キナーゼ活性化剤

Country Status (7)

Country Link
US (4) US8841305B2 (enExample)
EP (2) EP3173415B1 (enExample)
JP (2) JP5632379B2 (enExample)
AU (2) AU2009303335B2 (enExample)
CA (2) CA3041868C (enExample)
ES (1) ES2620634T3 (enExample)
WO (1) WO2010042867A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007281911B2 (en) 2006-08-04 2014-02-06 Beth Israel Deaconess Medical Center Inhibitors of pyruvate kinase and methods of treating disease
ES2620634T3 (es) 2008-10-09 2017-06-29 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Activadores de piruvato quinasa humana
JP5756457B2 (ja) 2009-04-06 2015-07-29 アジオス ファーマシューティカルズ, インコーポレイテッド ピルビン酸キナーゼm2調節剤、治療組成物および関連する使用方法
PL2427441T3 (pl) 2009-05-04 2017-06-30 Agios Pharmaceuticals, Inc. Aktywatory PKM2 do stosowania w leczeniu raka
DK2448581T3 (en) 2009-06-29 2017-03-13 Agios Pharmaceuticals Inc Therapeutic compositions and methods for their applications
PE20120693A1 (es) 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
CA2800498C (en) 2010-03-31 2021-11-16 The Scripps Research Institute Reprogramming cells
US20130109672A1 (en) * 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
WO2012056319A1 (en) * 2010-10-27 2012-05-03 Dynamix Pharmaceuticals Ltd. Sulfonamides for the modulation of pkm2
US9221792B2 (en) 2010-12-17 2015-12-29 Agios Pharmaceuticals, Inc N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators
WO2012088314A1 (en) 2010-12-21 2012-06-28 Agios Pharmaceuticals, Inc. Bicyclic pkm2 activators
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
WO2012151440A1 (en) * 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
PT3406251T (pt) 2011-05-03 2024-01-24 Agios Pharmaceuticals Inc Ativadores da piruvato-cinase para utilização em terapia
EP2704719B1 (en) 2011-05-03 2018-02-21 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
WO2013005157A1 (en) * 2011-07-05 2013-01-10 Lupin Limited Sulfone derivatives and their use as pkm2 modulators for the treatment of cancer
WO2013027168A1 (en) * 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
DE102012207707A1 (de) * 2012-05-09 2013-11-28 Deutsches Zentrum für Luft- und Raumfahrt e.V. Minimalinvasives Instrument für die robotische Chirurgie
EP2909181B1 (en) * 2012-10-16 2017-08-09 Tolero Pharmaceuticals, Inc. Pkm2 modulators and methods for their use
NZ707778A (en) * 2012-11-08 2019-03-29 Agios Pharmaceuticals Inc Therapeutic compounds and compositions and their use as pkm2 modulators
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
CN104370936A (zh) * 2014-09-28 2015-02-25 苏州维泰生物技术有限公司 一种新型丙酮酸激酶m2激活剂及其合成方法
MX384883B (es) 2015-06-11 2025-03-14 Agios Pharmaceuticals Inc Métodos para usar activadores de piruvato cinasa.
KR101713678B1 (ko) * 2015-08-24 2017-03-09 대우제약 주식회사 신규 화합물 4-Ethyl-7-(2-fluoro-benzylsulfanyl)-2-methyl-1-thia-3b, 5, 6-triaza-cyclopenta[a]indene 및 이를 포함하는 항암제용 약제학적 조성물
US11033998B2 (en) 2016-01-25 2021-06-15 The Regents Of The University Of California Binder compositions of tungsten tetraboride and abrasive methods thereof
AR111295A1 (es) * 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
EP3668513B1 (en) 2017-08-15 2021-11-10 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in treating blood disorders
US20200237766A1 (en) 2017-10-13 2020-07-30 Tolero Pharmaceuticals, Inc. Pkm2 activators in combination with reactive oxygen species for treatment of cancer
US12233063B2 (en) 2017-10-20 2025-02-25 The Regents Of The University Of Michigan Compositions and methods for treating eye disorders
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US20220127267A1 (en) * 2019-02-13 2022-04-28 Agios Pharmaceuticals, Inc. Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders
AU2020245437A1 (en) 2019-03-22 2021-09-30 Sumitomo Pharma Oncology, Inc. Compositions comprising PKM2 modulators and methods of treatment using the same
CN110483504B (zh) * 2019-08-02 2022-04-26 桂林理工大学 以DMF为甲酰化试剂构建2-(2-萘基)咪唑[1,2-a]吡啶-3-醛的新方法
MX2022003025A (es) 2019-09-19 2022-04-07 Forma Therapeutics Inc Activacion de la piruvato cinasa r.
DE102019129527A1 (de) 2019-10-31 2021-05-06 Forschungszentrum Jülich GmbH Inhibitoren für Bromodomänen
WO2021105115A1 (en) 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
US12478621B2 (en) 2019-11-28 2025-11-25 Deutsches Krebsforschungszentrum Substituted aminoquinolones as dgkalpha inhibitors for immune activation
US12337005B2 (en) 2020-05-26 2025-06-24 University Of Iowa Research Foundation Methods of treating thrombosis
EP4161886A4 (en) 2020-06-04 2023-12-27 Supermetalix, Inc. Metal boride ceramic composites and uses thereof
CA3183980A1 (en) * 2020-07-21 2022-01-27 The Regents Of The University Of Michigan Compositions and methods for activating pyruvate kinase
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
WO2023052783A1 (en) * 2021-09-30 2023-04-06 Sitryx Therapeutics Limited Novel compounds
CN118434720A (zh) 2021-12-22 2024-08-02 西特瑞治疗有限公司 作为丙酮酸激酶调节剂的酞嗪衍生物
CN115010721B (zh) * 2022-03-14 2023-06-13 五邑大学 一种荧光探针及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998828A (en) * 1975-01-31 1976-12-21 Pfizer Inc. 4-[2-(1,3-Dialkyl-1,2,3,4-tetra-hydropyrimidine-2,4-dione-5-carboxamido)ethyl]-1-piperidine sulfonamide
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
DE2948434A1 (de) * 1979-12-01 1981-06-11 Hoechst Ag, 6000 Frankfurt 1-piperidinsulfonylharnstoffe und verfahren zu ihrer herstellung
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4593102A (en) * 1984-04-10 1986-06-03 A. H. Robins Company, Inc. N-[(amino)alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulfur linked substitution in the 2, 3 or 4-position
US5019369A (en) * 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
JPH0667926B2 (ja) * 1985-11-12 1994-08-31 旭化成工業株式会社 環状のイソキノリンスルホンアミド誘導体
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
IT1252567B (it) * 1991-12-20 1995-06-19 Italfarmaco Spa Derivati di 5-isochinolinsolfonammidi inibitori delle protein-chinasi
DE69637380T2 (de) 1995-01-20 2009-09-17 G.D. Searle Llc, Chicago Bis-sulfonamid-hydroxyethylamino-derivate als inhibitoren retroviraler proteasen
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
PL351767A1 (en) * 1999-02-09 2003-06-16 Dimensional Pharmaceuticals 3 Heteroaryl amidines, methylamidines and guanidines as protease inhibitors
US6211182B1 (en) 1999-03-08 2001-04-03 Schering Corporation Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
IT1313592B1 (it) * 1999-08-03 2002-09-09 Novuspharma Spa Derivati di 1h-pirido 3,4-b indol-1-one.
AR032885A1 (es) * 2000-08-16 2003-12-03 Actelion Pharmaceuticals Ltd Bis-sulfonamidas, composiciones farmaceuticas, procedimiento para prepararlas y el uso de las mismas para la produccion de las composiciones farmaceuticas
DE60228233D1 (de) * 2001-05-23 2008-09-25 Max Planck Gesellschaft Pyruvat-kinase als einem neuen zielmolekül
EP1492794B1 (en) * 2002-03-28 2007-12-12 Eli Lilly And Company Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
AU2003237532B2 (en) * 2002-06-12 2009-07-30 Symphony Evolution, Inc. Human ADAM-10 inhibitors
WO2004016646A2 (en) * 2002-08-12 2004-02-26 Amynon Bio Tech Gmbh Peptide modulators of tumour specific pyruvate kinase subtype m2 (m2-pk)
US7754884B2 (en) * 2005-01-03 2010-07-13 Vanderbilt University Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging
WO2004076640A2 (en) * 2003-02-25 2004-09-10 Ambion, Inc. Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same
WO2005074946A1 (en) * 2004-02-10 2005-08-18 Adenobio N.V. Stable and active complexes of adenosine and adenosine phosphates with aminoalcohols for the treatment of pulmonary artery hypertension, cardiac failure and other diseases
WO2005080394A1 (en) * 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
US8058313B2 (en) * 2004-06-24 2011-11-15 Temple University—Of the Commonwealth System of Higher Education Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof
TW200606152A (en) 2004-07-02 2006-02-16 Tanabe Seiyaku Co Piperidine compound and process for preparing the same
FR2872704B1 (fr) 2004-07-12 2007-11-02 Laurent Schwartz Pluritherapie contre le cancer
WO2006055880A2 (en) * 2004-11-16 2006-05-26 Genzyme Corporation Diagnostic pkm2 methods and compositions
ES2430569T3 (es) * 2005-02-18 2013-11-21 Astrazeneca Ab Compuestos antibacterianos derivados de piperidina
EP1965799A2 (en) * 2005-12-22 2008-09-10 Merck & Co., Inc. Substituted piperidines as calcium channel blockers
EP1962851A2 (en) * 2005-12-22 2008-09-03 SmithKline Beecham Corporation Compounds
CN101404987A (zh) * 2006-01-20 2009-04-08 史密丝克莱恩比彻姆公司 磺酰胺衍生物在治疗代射和神经系统疾病中的用途
AU2007281911B2 (en) * 2006-08-04 2014-02-06 Beth Israel Deaconess Medical Center Inhibitors of pyruvate kinase and methods of treating disease
CL2007003223A1 (es) * 2006-11-10 2008-01-11 Wyeth Corp Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades.
EP2132169A1 (en) * 2007-03-05 2009-12-16 Biolipox AB New methylenebisphenyl compounds useful in the treatment of inflammation
WO2008130718A1 (en) * 2007-04-23 2008-10-30 Atherogenics, Inc. Sulfonamide containing compounds for treatment of inflammatory disorders
WO2009025781A1 (en) 2007-08-16 2009-02-26 Beth Israel Deaconess Medical Center Activators of pyruvate kinase m2 and methods of treating disease
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
ES2620634T3 (es) 2008-10-09 2017-06-29 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Activadores de piruvato quinasa humana
WO2011153359A1 (en) * 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof

Similar Documents

Publication Publication Date Title
DE602004024375D1 (de) Carboxamidderivate
JP2020521740A5 (enExample)
JP2013537203A5 (enExample)
JP2016503799A5 (enExample)
JP2016531126A5 (enExample)
JP2014511891A5 (enExample)
JP2015531366A5 (enExample)
HRP20180063T1 (hr) Lipidirani derivati imidazokinolina
JP2014511892A5 (enExample)
SE0300480D0 (sv) Novel compounds
JP2017519781A5 (enExample)
RU2016134751A (ru) Соединения
JP2009536660A5 (enExample)
JP2020520955A5 (enExample)
RU2009144848A (ru) Химические соединения-759
JP2005538089A5 (enExample)
RU2019142472A (ru) Глюкуронидные пролекарства ингибиторов янус-киназы
JP2017504635A5 (enExample)
JP2003306481A5 (enExample)
ATE386725T1 (de) Heterocyclylverbindungen
RU2015135824A (ru) Бициклические соединения пиримидона в качестве ингибиторов lp-pla2
CY1111022T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
SE0402925D0 (sv) Novel Compounds
RU2015135722A (ru) Дейтерированный фениламинопиримидин и фармацевтическая композиция, содержащая такое соединение
NO20060665L (no) N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer